Login
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc.

enliventherapeutics.com

What Do They Do?

Develops small-molecule drug candidates for people with chronic myeloid leukemia and researches treatments for other diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −37% (Loss)
vs −$20.1M in Q3 FY2025

From strategic review to drug development The older report described the company as having stopped research and development on its previous programs while evaluating strategic options. The latest report describes a clinical-stage small-molecule pipeline led by a candidate for chronic myeloid leukemia, alongside other research programs.

Who Do They Compete With?

Competes with Novartis, Bristol Myers Squibb, Pfizer, Takeda, Ascentage Pharma, Terns Pharmaceuticals, and TargetRx

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support